Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound
JE · Effective Nov 12, 2023
19 active Medicare policies list M75.92, and 2 commercial payer policies list it. See each policy's status for the code and its official source. Listing a code is not a coverage decision: read each policy’s source for the requirements that apply.
Free account. Policy pages stay open to everyone.
JE · Effective Nov 12, 2023
JF · Effective Nov 12, 2023
JJ · Effective Apr 30, 2023
JM · Effective Apr 30, 2023
J6
JK
J6 · Effective Oct 1, 2015
JK · Effective Oct 1, 2015
2 policies from 2 payers
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
| Policy | Effective | Status of M75.92 |
|---|---|---|
| Botulinum Toxin | Jan 1, 2024 | Covered |
| Policy | Effective | Status of M75.92 |
|---|---|---|
| Therapeutic use of Stem Cells, Blood and Bone Marrow Products | Oct 1, 2026 | Not covered |
National · Effective Oct 1, 2026
National · Effective Oct 1, 2026
J6 · Effective Oct 1, 2026
National · Effective Oct 1, 2025
J5 · Effective Oct 1, 2026
J9 · Effective Jan 1, 2026
JL · Effective Jan 1, 2026
National · Effective Oct 1, 2026
National · Effective Oct 1, 2026
National · Effective Oct 1, 2026
J6 · Effective Oct 25, 2026